![Willy Wiyatno](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Dr. Wiyatno joined Hercules Technology Capital Group in April 2006 focusing on the life science practice.
Prior to joining Hercules, he was a research scientist at Applied Biosystems (ABI) for four years where he focused on the development of emerging technologies in the areas of sample preparation, detection and analysis of DNA and proteins.
Willy is a lecturer at Stanford University and is currently pursuing his Chartered Financial Analyst accreditation.
He is an active board member of Golden Gate Polymer Forum (GGPF), a local non-profit organization dedicated to the advancement of materials and devices.
Willy obtained his Master and doctorate degrees in Chemical Engineering at Stanford University in 1999 and 2002, respectively.
He completed his bachelor degree at University of Wisconsin – Madison in 1997 in the area of Chemical Engineering.
Anciens postes connus de Willy Wiyatno
| Sociétés | Poste | Fin |
|---|---|---|
Hercules Capital
 Hercules Capital Investment ManagersFinance Hercules Capital invests in public and private companies located in the United States. The firm targets companies operating in the fields of technology and life science sectors. It provides financing in the form of debt and equity for acquisitions, growth stage capital requirements with a transaction size ranging from USD 5 to 500 million. | Analyste en capital-investissement | 30/06/2007 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
10
Relations au 1er degré
1
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Hercules Capital
Hercules Capital Investment ManagersFinance Hercules Capital invests in public and private companies located in the United States. The firm targets companies operating in the fields of technology and life science sectors. It provides financing in the form of debt and equity for acquisitions, growth stage capital requirements with a transaction size ranging from USD 5 to 500 million. | Finance |
